New Advances in Heart Diseases
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 30 June 2026 | Viewed by 31
Special Issue Editor
Interests: biologics; heart diseases; regenerative medicine; gene therapy; stem cell therapy; monoclonal antibodies; RNA therapeutics; precision cardiology; cardiovascular regeneration; inflammatory modulation
Special Issue Information
Dear Colleagues,
Heart diseases remain the leading cause of mortality worldwide, with traditional therapeutics often insufficient to halt progression or regenerate damaged cardiac tissue. The advent of biologics—therapeutic agents derived from living organisms—has introduced new paradigms in cardiovascular treatment. This Special Issue explores advancements in biologics, including monoclonal antibodies, gene therapies, stem cell interventions, and RNA-based therapeutics. It highlights recent breakthroughs in targeting inflammation, repairing myocardium, improving vascularization, and modulating immune responses. Future trends toward precision cardiology and regenerative medicine underscore biologics’ transformative potential in enhancing patient outcomes and redefining heart disease management.
Dr. Patrick Dunn
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biologics
- heart diseases
- regenerative medicine
- gene therapy
- stem cell therapy
- monoclonal antibodies
- RNA therapeutics
- precision cardiology
- cardiovascular regeneration
- inflammatory modulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
